Trump's Medicare Policy Changes for Weight-Loss Drug Costs

U.S. President Donald Trump has initiated a new policy aimed at cutting costs for weight-loss medications for Medicare beneficiaries, due to start on July 1. This announcement, highlighted during a speech at The Villages—a well-known retirement community in Florida—aims to address the financial burden of these treatments on seniors, according to Reuters.

The initiative particularly focuses on GLP-1-based weight-loss medications, which mimic natural gut hormones to regulate appetite. Notably, Danish pharmaceutical giant Novo Nordisk produces Wegovy, a popular GLP-1 treatment. Currently, Medicare beneficiaries can access Wegovy for $149 per month, though the cost is projected to rise to $199 per month by August 31, underlining the necessity for cost control in healthcare management.

Medicare serves as a crucial health insurance program for Americans aged 65 and older, and since his re-election in 2025, President Trump has been vocal about the exorbitant prices of weight-loss drugs. The U.S. government's agreement with Novo Nordisk in November helped secure lower prices, also involving Eli Lilly, a close competitor. President Trump's visit to The Villages is strategically timed ahead of the U.S. midterm elections, aiming to connect with older voters—a key demographic in these contests—following his first public appearance since a security incident at the Washington Correspondents’ Dinner.